Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | TLR2 | O60603 | 5/20 | 0.47 |
| ▸ | TLR1 | Q15399 | 2/20 | 0.47 |
| ▸ | GLP1R | P43220 | 8/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20450603 | 1.00 | KMT2A (0.57) | KMT2ATLR2TLR1GLP1RMEN1 | |
| SCHEMBL20450575 | 1.00 | KMT2A (0.57) | KMT2ATLR2TLR1GLP1RMEN1 | |
| SCHEMBL20450605 | 1.00 | KMT2A (0.57) | KMT2ATLR2TLR1GLP1RMEN1 | |
| SCHEMBL20450574 | 0.94 | KMT2A (0.49) | KMT2ATLR2TLR1GLP1RMEN1 | |
| SCHEMBL29617444 | 0.94 | KMT2A (0.49) | KMT2ATLR2TLR1GLP1RMEN1 | |
| SCHEMBL29617449 | 0.94 | KMT2A (0.49) | KMT2ATLR2TLR1GLP1RMEN1 | |
| SCHEMBL20450542 | 0.94 | KMT2A (0.49) | KMT2ATLR2TLR1GLP1RMEN1 | |
| SCHEMBL20450541 | 0.94 | KMT2A (0.49) | KMT2ATLR2TLR1GLP1RMEN1 | |
| SCHEMBL20450572 | 0.94 | KMT2A (0.49) | KMT2ATLR2TLR1GLP1RMEN1 | |
| SCHEMBL31758276 | 0.92 | KMT2A (0.67) | KMT2ATLR2TLR1MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3580232-B1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2023-09-20 | — | — | EP | disclosed |
| US-20220211812-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2022-07-07 | — | — | US | disclosed |
| US-11364281-B2 | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-06-21 | — | — | US | disclosed |
| US-11224634-B2 | — | — | 2022-01-18 | — | — | US | disclosed |
| US-11185570-B2 | Method of treating cardiovascular disease and heart failure with modified relaxin polypeptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-30 | — | — | US | disclosed |
| US-20210196791-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2021-07-01 | — | — | US | disclosed |
| US-20190256570-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-08-22 | — | — | US | disclosed |
| US-10266578-B2 | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180222960-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2018-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210196791-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | RXFP2, RXFP1, RXFP4 | KMT2A 2670/4885TLR2 1114/4885TLR1 1483/4885 |
| US-20190256570-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | RXFP2, RXFP1, RXFP4 | KMT2A 2670/4885TLR2 1114/4885TLR1 1483/4885 |
| US-20180222960-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | RXFP2, RXFP1, RXFP4 | KMT2A 2670/4885TLR2 1114/4885TLR1 1483/4885 |
| US-11364281-B2 | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof | RXFP2, RXFP1, RXFP4 | KMT2A 2556/4885TLR2 1015/4885TLR1 1451/4885 |
| US-20220211812-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | RXFP2, RXFP1, RXFP4 | KMT2A 2670/4885TLR2 1114/4885TLR1 1483/4885 |
| US-11224634-B2 | — | RXFP2, RXFP1, RXFP4 | KMT2A 2489/4885TLR2 1101/4885TLR1 2056/4885 |
| US-10266578-B2 | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof | RXFP2, RXFP1, RXFP4 | KMT2A 2670/4885TLR2 1114/4885TLR1 1483/4885 |
| US-11185570-B2 | Method of treating cardiovascular disease and heart failure with modified relaxin polypeptides | RXFP2, RXFP1, RXFP4 | KMT2A 1891/4885TLR2 1078/4885TLR1 1613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.